文献速递心力衰竭与心肌病

体重指数与疑似心衰患者NT-proBNP、症状及预后的关系

Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.
PubMed 文献 · Heart · 2026-02-09

在2866例因疑似心衰转诊至社区心衰门诊的患者中,校正年龄、性别、LVEF、肾功能、心律、症状和血压后,NT-proBNP浓度与BMI呈独立负相关,BMI每增加5 kg/m²,NT-proBNP低13%(95%CI 10%–17%)。但在NT-proBNP分层内,BMI与死亡率无关;NT-proBNP<125 ng/L者1年死亡率<1%,不受BMI影响。

要点

  • BMI每增加5 kg/m²,NT-proBNP浓度独立降低13%(95%CI 10%–17%)。
  • NT-proBNP分层内BMI与死亡率无关,其预后价值未因BMI而减弱。
  • NT-proBNP<125 ng/L者1年死亡率<1%,无论BMI高低。

核心结论

  • 在疑似心衰的门诊患者中,较高BMI与较低NT-proBNP浓度相关,但不削弱NT-proBNP的预后价值。
  • 为肥胖患者降低指南推荐的NT-proBNP阈值,不太可能识别出死亡风险更高的个体。

研究设计与样本

  • 2001年至2023年转诊至社区心衰门诊的患者,记录年龄、性别、BMI、血浆NT-proBNP、血肌酐、LVEF、NYHA分级、心律和收缩压。
  • 共纳入2866例患者,平均年龄71±11岁,63%为男性。
  • 按BMI分为消瘦(<25 kg/m²)、超重(25–29.9 kg/m²)和肥胖(≥30 kg/m²)三组。

主要发现

  • 校正年龄、性别、LVEF、肾功能、心律、症状和血压后,NT-proBNP浓度与BMI呈负相关(p<0.001)。
  • BMI每增加5 kg/m²,NT-proBNP低13%(95%CI 10%–17%)。
  • 在各NYHA分级内及大多数LVEF值范围内,较高BMI患者NT-proBNP浓度较低。
  • 在NT-proBNP分层内,BMI与死亡率无关。
  • NT-proBNP<125 ng/L者1年死亡率<1%,与BMI无关。

关键数值与推荐

  • BMI分组标准:消瘦<25 kg/m²,超重25–29.9 kg/m²,肥胖≥30 kg/m²。
  • NT-proBNP<125 ng/L者1年死亡率<1%。
  • BMI每增加5 kg/m²对应NT-proBNP低13%(95%CI 10%–17%)。

临床怎么用

  • 解读疑似心衰患者NT-proBNP时应考虑BMI对NT-proBNP浓度的稀释效应。
  • NT-proBNP<125 ng/L在肥胖患者中仍提示1年死亡风险<1%,无需因肥胖而下调该阈值。
  • NT-proBNP的预后判断价值不受BMI影响,可按常规阈值用于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Obesity is associated with lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, possibly because obese patients become symptomatic with less severe left ventricular dysfunction. We explored the relation among body mass index (BMI), left ventricular ejection fraction (LVEF), symptoms, NT-proBNP and mortality in ambulatory patients investigated for suspected heart failure (HF). METHODS: Between 2001 and 2023, patients referred to a community HF clinic had age, sex, BMI, plasma NT-proBNP, serum creatinine, LVEF, New York Heart Association (NYHA) class, cardiac rhythm and systolic blood pressure recorded. Patients were categorised as 'lean' BMI <25 kg/m2, 'overweight' BMI 25-29.9 kg/m2 or 'obese' BMI ≥30 kg/m2. RESULTS: Among 2866 patients (mean age 71±11 years; 63% men), NT-proBNP concentrations were inversely related to BMI after adjustment for age, sex, LVEF, renal function, rhythm, symptoms and blood pressure (p<0.001). Each 5 kg/m² increase in BMI was associated with a 13% (95% CI 10% to 17%) lower NT-proBNP. Within each NYHA class and across most LVEF values, patients with higher BMI had lower NT-proBNP concentrations. However, within NT-proBNP strata, BMI was not associated with mortality. Patients with NT-proBNP <125 ng/L had <1% 1-year mortality, irrespective of BMI. CONCLUSIONS: In ambulatory patients with suspected HF, higher BMI is associated with lower NT-proBNP concentrations but does not attenuate the prognostic value of NT-proBNP. Lowering guideline-recommended NT-proBNP thresholds for obese patients is unlikely to identify individuals at higher mortality risk.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Luo, Cuthbert, Kazmi, et al. Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure. Heart. 2026. PMID: 41663268. doi:10.1136/heartjnl-2025-327093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。